NCT04537351 (MEND) is a Phase 1 clinical trial of CYP-001 in Covid19, sponsored by Cynata Therapeutics Limited.

Who is sponsoring NCT04537351?

NCT04537351 is sponsored by Cynata Therapeutics Limited.

What drugs are being tested in NCT04537351?

Interventions in NCT04537351: CYP-001.

What condition does NCT04537351 study?

NCT04537351 studies Covid19, Acute Respiratory Distress Syndrome.

Is NCT04537351 still recruiting?

NCT04537351 is currently completed. Last updated 1 September 2023.

Last reviewed 2023-09-01 · How we verify

NCT04537351: MEND

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The MEseNchymal coviD-19 Trial: MSCs in Adults With Respiratory Failure Due to COVID-19 or Another Underlying Cause

Completed Phase 1 Last updated 1 September 2023

What this trial tests

Phase 1 trial testing CYP-001 in Covid19 in 14 participants. Completed in 18 May 2022.

Timeline

24 August 2020

Primary endpoint
27 April 2022

18 May 2022

Quick facts

Lead sponsor	Cynata Therapeutics Limited
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	14
Start date	24 August 2020
Primary completion	27 April 2022
Estimated completion	18 May 2022
Sites	5 locations across Australia

Drugs / interventions tested

CYP-001 — full drug profile →

Conditions studied

Covid19 — all drugs for Covid19 →
Acute Respiratory Distress Syndrome — all drugs for Acute Respiratory Distress Syndrome →

Sponsor

Cynata Therapeutics Limited — full company profile →

Who can join

18 and older, any sex, with Covid19 or Acute Respiratory Distress Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a pilot, multi-centre, open-label randomised controlled study to assess the early efficacy of intravenous (IV) administration of CYP-001 in adults admitted to an intensive care unit (ICU) with respiratory failure

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Induced pluripotent stem cells (iPSCs): molecular mechanisms of induction and applications.
Cerneckis J, Cai H, Shi Y. · · 2024 · cited 248× · PMID 38670977 · DOI 10.1038/s41392-024-01809-0
Mesenchymal stem/stromal cells as a valuable source for the treatment of immune-mediated disorders.
Markov A, Thangavelu L, Aravindhan S, Zekiy AO, et al · · 2021 · cited 174× · PMID 33736695 · DOI 10.1186/s13287-021-02265-1
Review of the Current Trends in Clinical Trials Involving Induced Pluripotent Stem Cells.
Kim JY, Nam Y, Rim YA, Ju JH. · · 2022 · cited 80× · PMID 34532844 · DOI 10.1007/s12015-021-10262-3
Human Induced Pluripotent Stem Cell-Derived Mesenchymal Stem Cells Acquire Rejuvenation and Reduced Heterogeneity.
Wruck W, Graffmann N, Spitzhorn LS, Adjaye J. · · 2021 · cited 48× · PMID 34604216 · DOI 10.3389/fcell.2021.717772
Fit-For-All iPSC-Derived Cell Therapies and Their Evaluation in Humanized Mice With NK Cell Immunity.
Flahou C, Morishima T, Takizawa H, Sugimoto N. · · 2021 · cited 45× · PMID 33897711 · DOI 10.3389/fimmu.2021.662360
Regulation of Inflammatory Cytokine Storms by Mesenchymal Stem Cells.
Wang L, Li Y, Xu M, Deng Z, et al · · 2021 · cited 38× · PMID 34394132 · DOI 10.3389/fimmu.2021.726909
Mesenchymal stem cell-based therapy and exosomes in COVID-19: current trends and prospects.
Abdelgawad M, Bakry NS, Farghali AA, Abdel-Latif A, et al · · 2021 · cited 33× · PMID 34419143 · DOI 10.1186/s13287-021-02542-z
Mesenchymal stem cell-based treatments for COVID-19: status and future perspectives for clinical applications.
Chen L, Qu J, Kalyani FS, Zhang Q, et al · · 2022 · cited 31× · PMID 35187617 · DOI 10.1007/s00018-021-04096-y

Verify or expand the search:

Other recruiting trials for Covid19

Currently open trials in the same condition.

NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting

Other Cynata Therapeutics Limited trials

Trials by the same sponsor.

NCT05165628 — Safety, Tolerability and Efficacy of CYP-006TK in Adults with Diabetic Foot Ulcers · Phase 1 · completed
NCT02923375 — A Study of CYP-001 for the Treatment of Steroid-Resistant Acute Graft Versus Host Disease · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04537351 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cynata Therapeutics Limited
Last refreshed: 1 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04537351.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing